Profile data is unavailable for this security.
About the company
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
- Revenue in USD (TTM)423.75m
- Net income in USD153.67m
- Incorporated2008
- Employees581.00
- LocationInmode LtdTavor Building, Sha'ar Yokneam, Pob 533YOKNEAM 2069200IsraelISR
- Phone+972 49097470
- Websitehttps://inmodemd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Artivion Inc | 376.97m | -8.32m | 1.20bn | 1.50k | -- | 4.07 | 80.13 | 3.19 | -0.2076 | -0.2076 | 9.11 | 7.06 | 0.481 | 1.67 | 5.44 | 251,316.00 | -1.07 | -2.20 | -1.15 | -2.36 | 64.63 | 65.51 | -2.22 | -5.34 | 4.04 | 1.07 | 0.5177 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
| BioLife Solutions Inc | 121.17m | -53.87m | 1.21bn | 409.00 | -- | 3.75 | -- | 9.95 | -1.21 | -1.64 | 2.69 | 6.97 | 0.2999 | 1.99 | 5.39 | 296,254.30 | -13.33 | -13.76 | -14.60 | -15.04 | 41.27 | 36.76 | -44.46 | -42.99 | 1.81 | -5.98 | 0.0651 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
| Pulse Biosciences Inc | 0.00 | -46.13m | 1.22bn | 56.00 | -- | 15.45 | -- | -- | -0.8069 | -0.8069 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -58.03 | -93.21 | -62.84 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Establishment Labs Holdings Inc | 151.35m | -83.20m | 1.29bn | 857.00 | -- | 28.71 | -- | 8.54 | -3.11 | -3.11 | 5.62 | 1.61 | 0.5307 | 0.8525 | 2.72 | 166,685.00 | -29.17 | -33.22 | -34.29 | -41.12 | 66.04 | 64.73 | -54.97 | -43.19 | 2.91 | -20.68 | 0.8114 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
| Alphatec Holdings Inc | 572.74m | -177.87m | 1.33bn | 839.00 | -- | -- | -- | 2.33 | -1.27 | -1.27 | 4.08 | 0.1546 | 0.8089 | 1.11 | 7.73 | 682,644.80 | -25.12 | -30.97 | -32.00 | -39.47 | 69.47 | 66.02 | -31.06 | -46.22 | 1.15 | -3.66 | 0.9596 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Adapthealth Corp | 3.26bn | -217.76m | 1.36bn | 10.70k | -- | 0.8953 | 8.24 | 0.4161 | -1.64 | -1.64 | 24.23 | 11.27 | 0.7096 | 21.15 | 8.45 | 304,912.50 | -4.57 | -4.34 | -5.14 | -4.89 | 19.03 | 18.28 | -6.44 | -6.47 | 0.9951 | 2.29 | 0.5757 | -- | 7.73 | -- | -1,169.99 | -- | -- | -- |
| STAAR Surgical Co | 341.22m | 21.78m | 1.46bn | 1.06k | 67.54 | 3.41 | 52.71 | 4.27 | 0.4381 | 0.4381 | 6.90 | 8.69 | 0.6763 | 2.03 | 3.15 | 323,128.80 | 4.32 | 6.77 | 4.92 | 7.90 | 78.73 | 76.89 | 6.38 | 9.16 | 5.38 | -- | 0.0002 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Inmode Ltd | 423.75m | 153.67m | 1.48bn | 581.00 | 10.51 | 2.18 | 9.59 | 3.49 | 1.85 | 1.85 | 5.04 | 8.92 | 0.5239 | 1.58 | 10.15 | 729,339.10 | 19.00 | 31.32 | 20.77 | 35.64 | 81.64 | 84.46 | 36.26 | 39.65 | 9.91 | -- | 0.00 | 0.00 | 8.32 | 37.49 | 22.54 | 54.65 | 13.10 | -- |
| Evolent Health Inc | 2.35bn | -106.20m | 1.55bn | 4.70k | -- | 1.45 | 101.49 | 0.66 | -0.9367 | -0.9367 | 20.71 | 10.79 | 0.9191 | -- | 6.55 | 500,823.00 | -2.91 | -9.60 | -3.63 | -12.59 | 18.57 | 24.50 | -3.16 | -13.66 | -- | -0.2382 | 0.326 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
| Myriad Genetics, Inc. | 802.20m | -155.20m | 1.58bn | 2.70k | -- | 2.14 | -- | 1.97 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| AtriCure Inc | 447.57m | -38.92m | 1.83bn | 1.20k | -- | 3.93 | -- | 4.08 | -0.8322 | -0.8322 | 9.56 | 9.54 | 0.7365 | 1.63 | 8.41 | 372,977.50 | -6.40 | -3.72 | -7.35 | -4.10 | 74.79 | 74.36 | -8.70 | -7.64 | 2.59 | -13.76 | 0.1194 | -- | 20.84 | 14.64 | 34.49 | -- | 46.56 | -- |
| Patterson Companies, Inc. | 6.53bn | 168.41m | 1.83bn | 7.60k | 11.37 | 1.93 | 7.11 | 0.2806 | 1.83 | 1.83 | 71.22 | 10.80 | 2.27 | 5.86 | 15.35 | 859,640.70 | 5.84 | 1.13 | 10.15 | 1.81 | 21.03 | 20.98 | 2.57 | 0.5157 | 0.6723 | 7.91 | 0.4474 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Novocure Ltd | 577.74m | -149.78m | 1.89bn | 1.45k | -- | 5.23 | -- | 3.27 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| 10X Genomics Inc | 629.74m | -182.55m | 1.89bn | 1.26k | -- | 2.62 | -- | 3.01 | -1.53 | -1.53 | 5.26 | 5.97 | 0.6677 | 2.40 | 6.72 | 500,193.00 | -19.36 | -25.52 | -21.99 | -29.05 | 66.63 | 75.88 | -28.99 | -48.53 | 4.12 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Rxsight Inc | 115.18m | -36.77m | 1.91bn | 374.00 | -- | 6.91 | -- | 16.54 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Integra Lifesciences Holdings Corp | 1.56bn | -6.54m | 1.91bn | 3.95k | -- | 1.26 | 14.97 | 1.22 | -0.0881 | -0.0881 | 20.22 | 19.73 | 0.401 | 1.59 | 5.99 | 396,583.90 | -0.1677 | 3.33 | -0.2002 | 3.68 | 59.29 | 63.67 | -0.4182 | 7.99 | 0.7261 | 4.05 | 0.5428 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
Data as of Nov 08 2024. Currency figures normalised to Inmode Ltd's reporting currency: US Dollar USD
25.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.62m | 6.64% |
| Fidelity Investments Canada ULCas of 30 Jun 2024 | 2.84m | 3.36% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 2.07m | 2.44% |
| DOMA Perpetual Capital Management LLCas of 30 Jun 2024 | 2.01m | 2.38% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.97m | 2.33% |
| LSV Asset Managementas of 30 Jun 2024 | 1.86m | 2.20% |
| Boston Trust Walden, Inc.as of 30 Sep 2024 | 1.41m | 1.66% |
| Meitav Mutual Funds Ltd.as of 30 Sep 2024 | 1.35m | 1.60% |
| DDD Partners LLCas of 30 Jun 2024 | 1.27m | 1.50% |
| Menora Mivtachim Insurance Ltd.as of 30 Jun 2024 | 1.17m | 1.39% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
